[Cabozantinib: Mechanism of action, efficacy and indications].

Related Articles

[Cabozantinib: Mechanism of action, efficacy and indications].

Bull Cancer. 2017 May 03;:

Authors: Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S

Abstract
Cabozantinib is an oral multiple tyrosine kinase receptor inhibitor (ITK): VEGFR2, c-MET and RET. Inhibition of VEGFR and c-MET decrease resistance of VEGFR inhibitor via c-MET axis. Cabozantinib improve progression-free survival (PFS) in progressive metastatic medullary thyroid cancer (MTC): 4 months in the placebo group and 11.2 months in the cabozantinib group (P<0.001) in all patient subgroups including those with or without prior ITK and RET mutation status. Cabozantinib increased overall survival (OS) compared with everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR ITK treatment: 21.4 months in cabozantinib group and 16.5 months in everolimus group (P<0.0003). Cabozantinib obtained the AMM for the treatment of progressive metastatic MTC and advanced renal cell carcinoma. Cabozantinib is a new option in the treatment of MTC by inclusion in therapeutic trials (no payment in this indication) and advanced renal cell carcinoma (hospital delivery). Its tolerance is similar to anti-angiogenic therapies and justifies an optimal management of the secondary effect.

PMID: 28477875 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2pyobXU
via IFTTT